Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III
After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the GLP1-RA class, while reporting mid-stage data for its GLP1- and amylin-targeting drug amycretin that raised dosing questions.
Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III Read More »
